TheraSphere mechanism of action explained
TheraSphere Y-90 glass microspheres are uniquely engineered to have unmatched radiation per microsphere (RPM). This allows TheraSphere to maximize repetitive and cumulative radiation exposure to tumor cells to achieve complete pathological necrosis (CPN) at ablative doses. With data since 1999 that spans the BCLC algorithm, TheraSphere is an FDA approved Y-90 therapy for HCC and is backed by positive level 1 clinical evidence.
At the time of publication of this animation, TheraSphere operated with a single Sunday calibration day. TheraSphere now operates with two calibration days—Thursday and Sunday. Accordingly, references in this asset to ‘Week 1’ or ‘Week 2’ correspond to days post-calibration from Sunday calibration (For example, first week Monday equates to 1 day-post calibration and second week Friday equates to 12 days-post calibration).